AUTHOR=Nuersulitan Reyizha , Li Miaomiao , Mi Lan , Wu Meng , Ji Xinqiang , Liu Yiqi , Zhao Hong , Wang Guiqiang , Song Yuqin , Zhu Jun , Liu Weiping 

TITLE=Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.989258

DOI=10.3389/fonc.2022.989258

ISSN=2234-943X

ABSTRACT=Patients with lymphoma who are also infected with Hepatitis B virus (HBV) have a poor prognosis. This could be partly explained by the delay or premature termination of anti-tumor treatment because of HBV reactivation. However, there is limited data on the survival outcome of patients HBV-related lymphoma in the era of prophylactic antivirals. Data for 128 patients with HBV surface antigen-positive diffuse large B-cell lymphoma was collected. The median age was 54 years and the ratio of men to women was 1.2:1. All patients received immune-chemotherapy and prophylactic antiviral therapy. The median number of cycles of immune-chemotherapy were six. The overall response rate was 82% with a complete remission rate of 75%. With a median follow-up of 58.4 months, the 5-year progression-free survival and overall survival rates were 75.7 % and 74.7%, respectively. Nine patients experienced HBV reactivation and one experienced HBV-related hepatitis. Patients with low and high HBV DNA loads had comparable survival outcomes. In conclusion, patients with HBV related lymphoma treated with prophylactic antivirals did not have a poorer prognosis compared with non-HBV infected patients.